Researchers launch Spermine Risk Score for prostate cancer diagnosis

Researchers grow intestinal cells from human-induced pluripotent stem cells
8 February 2021
Hospitalized health care workers do not have worse COVID-19 outcomes
8 February 2021

Researchers launch Spermine Risk Score for prostate cancer diagnosis

Researchers from Hong Kong Baptist University (HKBU) and the Faculty of Medicine at The Chinese University of Hong Kong (CU Medicine) have jointly developed the Spermine Risk Score which, coupled with the use of a urine test, provides a non-invasive and more reliable method for the diagnosis of prostate cancer. In a study conducted by the researchers, about 37% of the patients, who were ultimately found to have no prostate cancer, can avoid undergoing a prostate biopsy procedure. The findings have just been published in the scientific journal Prostate Cancer and Prostatic Diseases.

Comments are closed.